Voya Investment Management LLC Lowers Holdings in Haemonetics Corporation $HAE

Key Points

• Voya Investment Management LLC significantly reduced its stake in Haemonetics Corporation by 81.5%, selling 258,200 shares and now holding about 58,752 shares valued at approximately $3.73 million.
• Haemonetics reported a quarterly earnings per share (EPS) of $1.10, beating analysts' expectations, while its revenue of $321.39 million declined by 4.4% year-over-year.
• Multiple analysts have adjusted their price targets for Haemonetics, with Mizuho lowering its target from $90.00 to $70.00, indicating a generally bearish outlook on the stock.

Voya Investment Management LLC lowered its position in Haemonetics Corporation (NYSE:HAE - Free Report) by 81.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,752 shares of the medical instruments supplier's stock after selling 258,200 shares during the quarter. Voya Investment Management LLC owned approximately 0.12% of Haemonetics worth $3,734,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in the business. Inspire Investing LLC raised its position in Haemonetics by 5.9% in the 1st quarter. Inspire Investing LLC now owns 5,441 shares of the medical instruments supplier's stock worth $346,000 after purchasing an additional 304 shares during the period. Rhumbline Advisers grew its stake in shares of Haemonetics by 1.2% during the first quarter. Rhumbline Advisers now owns 161,123 shares of the medical instruments supplier's stock valued at $10,239,000 after buying an additional 1,861 shares during the last quarter. Strs Ohio bought a new position in shares of Haemonetics during the first quarter valued at about $140,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier's stock valued at $9,923,000 after buying an additional 9,051 shares during the last quarter. Finally, Empowered Funds LLC boosted its holdings in Haemonetics by 9.1% during the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier's stock valued at $283,000 after acquiring an additional 372 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

HAE has been the subject of several analyst reports. Barrington Research dropped their target price on Haemonetics from $95.00 to $86.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Citigroup upgraded Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price objective for the company in a research report on Wednesday, July 9th. Mizuho decreased their target price on shares of Haemonetics from $90.00 to $70.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Robert W. Baird initiated coverage on shares of Haemonetics in a report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price target on the stock. Finally, Baird R W raised shares of Haemonetics to a "strong-buy" rating in a report on Wednesday, June 25th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Haemonetics presently has an average rating of "Moderate Buy" and an average price target of $78.78.

Haemonetics Trading Down 0.1%

Shares of NYSE:HAE traded down $0.04 on Tuesday, hitting $51.14. The company had a trading volume of 95,833 shares, compared to its average volume of 839,849. Haemonetics Corporation has a 1 year low of $49.43 and a 1 year high of $94.99. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of 15.64, a P/E/G ratio of 0.93 and a beta of 0.39. The firm's 50-day simple moving average is $60.69 and its two-hundred day simple moving average is $64.72. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.09. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The company had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. During the same period in the previous year, the company posted $1.02 earnings per share. The firm's revenue was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Equities analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.